This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the latest trading session, Adma Biologics (ADMA) closed at $18.59, marking a +1.81% move from the previous day.
Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
The latest trading day saw Adma Biologics (ADMA) settling at $18.26, representing a +1.44% change from its previous close.
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
by Zacks Equity Research
Adma Biologics (ADMA) concluded the recent trading session at $17.13, signifying a +2.39% move from its prior day's close.
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the most recent trading session, Adma Biologics (ADMA) closed at $17.98, indicating a -3.75% shift from the previous trading day.
Adma Biologics (ADMA) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
Adma Biologics (ADMA) concluded the recent trading session at $18.34, signifying a +2.98% move from its prior day's close.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Adma Biologics (ADMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Adma Biologics (ADMA) closed at $18.16 in the latest trading session, marking a -1.3% move from the prior day.
Implied Volatility Surging for ADMA Biologics Stock Options
by Zacks Equity Research
Investors need to pay close attention to ADMA stock based on the movements in the options market lately.
Will Strong Asceniv Sales Drive ADMA Biologics Further?
by Ekta Bagri
ADMA rides on record Asceniv sales and FDA-backed yield boost, but valuation concerns and EPS downgrades cloud its outlook.
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
by Ekta Bagri
ADMA's surging Asceniv demand and bold revenue forecasts set it apart in the competitive plasma therapies space.
Here's Why Adma Biologics (ADMA) Fell More Than Broader Market
by Zacks Equity Research
Adma Biologics (ADMA) closed the most recent trading day at $17.74, moving 2.15% from the previous trading session.
ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
by Zacks Equity Research
ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.
Is Invesco S&P SmallCap Quality ETF (XSHQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XSHQ
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
by Ekta Bagri
ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.
Should Invesco S&P SmallCap Quality ETF (XSHQ) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for XSHQ
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
by Ekta Bagri
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
Are Options Traders Betting on a Big Move in ADMA Biologics Stock?
by Zacks Equity Research
Investors need to pay close attention to ADMA Biologics stock based on the movements in the options market lately.
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
by Zacks Equity Research
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.
RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Rocket Pharmaceuticals incurs a narrower-than-expected first-quarter 2025 loss. The company provides updates on its pipeline candidates.
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Puma Biotechnology beats on first-quarter 2025 earnings and sales. Stock rises in after-hours trading
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
by Ekta Bagri
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025. We recommend the stock to prospective investors.
Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains
by Zacks Equity Research
VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y
by Zacks Equity Research
CPRX reports strong first-quarter 2025 results, beating earnings and revenue estimates, primarily driven by Firdapse sales.